TriangleBrigatinib (NCT04374305)
Brigatinib trial for Neurofibromatosis Type 2 (NCT04374305). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 12+ with NF2-related schwannomatosis and growing schwannomas, meningiomas or ependymomas when surgery is unsuitable or declined.
The idea: test neratinib, which blocks growth signals, or retifanlimab plus bevacizumab, targeting immune brakes and tumor blood vessels. Neratinib requires weight of at least 40 kilograms; the combination is for ages 12–25. The brigatinib arm is closed. Researchers measure tumor shrinkage and safety.
This phase 2 study plans 109 patients. Scott Plotkin leads at Massachusetts General Hospital; five US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.